Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07164027 · ClinicalTrials.gov registry record · Early Phase 1

Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial

A Early Phase 1 study of Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

Compiled by PlainTrial · August 8, 2026

Recruiting
Registry status: Early Phase 1
Development phase: 30
Enrollment target: 1
Study location

NCT07164027: Recruiting Early Phase 1 study of Prostate Carcinoma, sponsored by Jonsson Comprehensive Cancer Center.

NCT07164027 is a Early Phase 1 study of Prostate Carcinoma that is actively recruiting participants, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 30 participants, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07164027, a Early Phase 1 study of Prostate Carcinoma, is actively recruiting participants, sponsored by Jonsson Comprehensive Cancer Center.

RECRUITING
Registry status: Early Phase 1
Development phase: 30 participants
Enrollment target: 1
Study location

Study Summary

This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate cancer. Flotufolastat F 18 is a radioactive imaging agent that binds to prostate tumor cells that express PSMA. This allows for visualization of PSMA-expressing tumor cells on imaging scans such as PET/CT. PET is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of tracer, in the case of this research, flotufolastat F 18. Because prostate cancer takes up flotufolastat F 18, it can be seen with PET. CT utilizes X-rays that track the body from the outside. CT images provide an exact outline of organs and potential inflammatory tissue where it occurs in the body. The PET/CT scanner combines the PET and the CT scanners into a single device. A targeted prostate biopsy refers to using advanced imaging for guidance when taking samples (biopsies) of the prostate. This method can fuse (combine) PET/CT images with real-time ultrasound during a prostate biopsy. PSMA PET/CT scans have the potential for guiding prostate biopsies. Using image fusion technology, they can increase detection of prostate cancer by providing anatomical information and guidance during a prostate biopsy. Improved detection of prostate cancer using PSMA PET/CT guidance may better inform men and their clinicians about prostate cancer risk and management. This study attempts to determine how often prostate cancer is found when using PSMA PET/CT scan images during a biopsy versus the conventional magnetic resonance imaging-guidance.

Primary Outcome

Results of prostate specific membrane antigen (PSMA)- and magnetic resonance imaging (MRI)-guided biopsy will be compared to the results of systematic biopsy in the same patient.

Conditions Studied

Prostate Carcinoma

Interventions

PROCEDURE Biospecimen Collection
PROCEDURE Computed Tomography
PROCEDURE Positron Emission Tomography
PROCEDURE Biopsy of Prostate
RADIATION Flotufolastat F-18 Gallium

Study Locations (1)

California

UCLA / Jonsson Comprehensive Cancer Center - Los Angeles

Trial Details

Field	Value
Enrollment Target	30 participants
Start Date	2025-11-14
Est. Completion	2037-01-28
Phase	Early Phase 1

Jonsson Comprehensive Cancer Center

321 total trials

What NCT07164027 shows while recruiting

NCT07164027 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,501-participant average among 59 other Prostate Carcinoma trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Prostate Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.

NCT07164027 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT07164027 about?

NCT07164027 is a clinical study titled "Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial". This early phase I trial evaluates whether a new imaging technique using flotufolastat F 18 (a type of prostate specific membrane antigen \[PSMA\] imaging agent) with positron emission tomography (PET)/computed tomography (CT) can be used to guide targeted prostate biopsies in men with prostate canc...

What is the current status of trial NCT07164027?

This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2025-11-14. Estimated completion is 2037-01-28.

What conditions does trial NCT07164027 study?

This clinical trial studies the following conditions: Prostate Carcinoma.

What interventions are being tested in trial NCT07164027?

The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (PROCEDURE), Positron Emission Tomography (PROCEDURE), Biopsy of Prostate (PROCEDURE), Flotufolastat F-18 Gallium (RADIATION).

Who is sponsoring clinical trial NCT07164027?

This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07164027 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07164027's enrollment target sits among peer trials

30 48th of 59 higher than 9 of 59 other Prostate Carcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07164027, the US trial registry maintained by the National Library of Medicine. NCT07164027 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.